How  ||| S:0 E:4 ||| WRB
HCV  ||| S:4 E:8 ||| NNP
has  ||| S:8 E:12 ||| VBZ
changed  ||| S:12 E:20 ||| VBN
the  ||| S:20 E:24 ||| DT
approach  ||| S:24 E:33 ||| NN
to  ||| S:33 E:36 ||| TO
mixed  ||| S:36 E:42 ||| JJ
cryoglobulinemia  ||| S:42 E:59 ||| JJ
Mixed  ||| S:59 E:65 ||| JJ
cryoglobulinemia  ||| S:65 E:82 ||| NN
is  ||| S:82 E:85 ||| VBZ
a  ||| S:85 E:87 ||| DT
systemic  ||| S:87 E:96 ||| JJ
disease  ||| S:96 E:104 ||| NN
due  ||| S:104 E:108 ||| JJ
to  ||| S:108 E:111 ||| TO
a  ||| S:111 E:113 ||| DT
small  ||| S:113 E:119 ||| JJ
vessel  ||| S:119 E:126 ||| NN
immune-complex  ||| S:126 E:141 ||| JJ
mediated  ||| S:141 E:150 ||| JJ
vasculitis ||| S:150 E:160 ||| NN
.  ||| S:160 E:162 ||| .
The  ||| S:162 E:166 ||| DT
discovery  ||| S:166 E:176 ||| NN
of  ||| S:176 E:179 ||| IN
a  ||| S:179 E:181 ||| DT
viral  ||| S:181 E:187 ||| JJ
origin  ||| S:187 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
the  ||| S:197 E:201 ||| DT
disease  ||| S:201 E:209 ||| NN
has  ||| S:209 E:213 ||| VBZ
launched  ||| S:213 E:222 ||| VBN
a  ||| S:222 E:224 ||| DT
great  ||| S:224 E:230 ||| JJ
expectancy  ||| S:230 E:241 ||| NN
among  ||| S:241 E:247 ||| IN
researchers  ||| S:247 E:259 ||| NNS
and  ||| S:259 E:263 ||| CC
the  ||| S:263 E:267 ||| DT
years  ||| S:267 E:273 ||| NNS
after  ||| S:273 E:279 ||| IN
this  ||| S:279 E:284 ||| DT
finding  ||| S:284 E:292 ||| NN
have  ||| S:292 E:297 ||| VBP
been  ||| S:297 E:302 ||| VBN
characterized  ||| S:302 E:316 ||| VBN
by  ||| S:316 E:319 ||| IN
the  ||| S:319 E:323 ||| DT
effort  ||| S:323 E:330 ||| NN
to  ||| S:330 E:333 ||| TO
reach  ||| S:333 E:339 ||| VB
viral  ||| S:339 E:345 ||| JJ
eradication  ||| S:345 E:357 ||| NN
in  ||| S:357 E:360 ||| IN
the  ||| S:360 E:364 ||| DT
hope  ||| S:364 E:369 ||| NN
of  ||| S:369 E:372 ||| IN
obtaining  ||| S:372 E:382 ||| VBG
disease  ||| S:382 E:390 ||| NN
remission ||| S:390 E:399 ||| NN
.  ||| S:399 E:401 ||| .
Moreover ||| S:401 E:409 ||| RB
,  ||| S:409 E:411 ||| ,
the  ||| S:411 E:415 ||| DT
use  ||| S:415 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
immunosuppressives  ||| S:422 E:441 ||| NN
has  ||| S:441 E:445 ||| VBZ
been  ||| S:445 E:450 ||| VBN
discouraged  ||| S:450 E:462 ||| VBN
for  ||| S:462 E:466 ||| IN
many  ||| S:466 E:471 ||| JJ
years  ||| S:471 E:477 ||| NNS
as  ||| S:477 E:480 ||| IN
they  ||| S:480 E:485 ||| PRP
could  ||| S:485 E:491 ||| MD
favour  ||| S:491 E:498 ||| VB
viral  ||| S:498 E:504 ||| JJ
replication ||| S:504 E:515 ||| NN
,  ||| S:515 E:517 ||| ,
and  ||| S:517 E:521 ||| CC
HCV  ||| S:521 E:525 ||| NNP
infection  ||| S:525 E:535 ||| NN
has  ||| S:535 E:539 ||| VBZ
represented  ||| S:539 E:551 ||| VBN
a  ||| S:551 E:553 ||| DT
contraindication  ||| S:553 E:570 ||| NN
to  ||| S:570 E:573 ||| TO
the  ||| S:573 E:577 ||| DT
more  ||| S:577 E:582 ||| RBR
recent  ||| S:582 E:589 ||| JJ
biological  ||| S:589 E:600 ||| JJ
drugs  ||| S:600 E:606 ||| NNS
directed  ||| S:606 E:615 ||| VBN
against  ||| S:615 E:623 ||| IN
cytokines ||| S:623 E:632 ||| NN
.  ||| S:632 E:634 ||| .
The  ||| S:634 E:638 ||| DT
trials  ||| S:638 E:645 ||| NNS
with  ||| S:645 E:650 ||| IN
antiviral  ||| S:650 E:660 ||| JJ
agents  ||| S:660 E:667 ||| NNS
in  ||| S:667 E:670 ||| IN
this  ||| S:670 E:675 ||| DT
disorder ||| S:675 E:683 ||| NN
,  ||| S:683 E:685 ||| ,
however ||| S:685 E:692 ||| RB
,  ||| S:692 E:694 ||| ,
has  ||| S:694 E:698 ||| VBZ
not  ||| S:698 E:702 ||| RB
met  ||| S:702 E:706 ||| VBD
the  ||| S:706 E:710 ||| DT
expectations ||| S:710 E:722 ||| NNS
,  ||| S:722 E:724 ||| ,
especially  ||| S:724 E:735 ||| RB
when  ||| S:735 E:740 ||| WRB
challenged  ||| S:740 E:751 ||| VBN
with  ||| S:751 E:756 ||| IN
some  ||| S:756 E:761 ||| DT
of  ||| S:761 E:764 ||| IN
the  ||| S:764 E:768 ||| DT
most  ||| S:768 E:773 ||| RBS
severe  ||| S:773 E:780 ||| JJ
complications  ||| S:780 E:794 ||| NNS
of  ||| S:794 E:797 ||| IN
the  ||| S:797 E:801 ||| DT
disease ||| S:801 E:808 ||| NN
;  ||| S:808 E:810 ||| :
moreover ||| S:810 E:818 ||| RB
,  ||| S:818 E:820 ||| ,
these  ||| S:820 E:826 ||| DT
medications  ||| S:826 E:838 ||| NN
were  ||| S:838 E:843 ||| VBD
not  ||| S:843 E:847 ||| RB
devoid  ||| S:847 E:854 ||| VBN
of  ||| S:854 E:857 ||| IN
unexpected  ||| S:857 E:868 ||| JJ
side  ||| S:868 E:873 ||| NN
effects ||| S:873 E:880 ||| NNS
,  ||| S:880 E:882 ||| ,
such  ||| S:882 E:887 ||| JJ
as  ||| S:887 E:890 ||| IN
the  ||| S:890 E:894 ||| DT
occurrence  ||| S:894 E:905 ||| NN
of  ||| S:905 E:908 ||| IN
peripheral  ||| S:908 E:919 ||| JJ
neuropathies ||| S:919 E:931 ||| NN
.  ||| S:931 E:933 ||| .
Since  ||| S:933 E:939 ||| IN
lymphoproliferation  ||| S:939 E:959 ||| NN
is  ||| S:959 E:962 ||| VBZ
one  ||| S:962 E:966 ||| CD
of  ||| S:966 E:969 ||| IN
the  ||| S:969 E:973 ||| DT
features  ||| S:973 E:982 ||| NNS
of  ||| S:982 E:985 ||| IN
the  ||| S:985 E:989 ||| DT
disease ||| S:989 E:996 ||| NN
,  ||| S:996 E:998 ||| ,
this  ||| S:998 E:1003 ||| DT
has  ||| S:1003 E:1007 ||| VBZ
focused  ||| S:1007 E:1015 ||| VBN
the  ||| S:1015 E:1019 ||| DT
attention  ||| S:1019 E:1029 ||| NN
of  ||| S:1029 E:1032 ||| IN
investigators  ||| S:1032 E:1046 ||| NNS
on  ||| S:1046 E:1049 ||| IN
the  ||| S:1049 E:1053 ||| DT
potential  ||| S:1053 E:1063 ||| JJ
benefit  ||| S:1063 E:1071 ||| NN
of  ||| S:1071 E:1074 ||| IN
newly  ||| S:1074 E:1080 ||| RB
targeted  ||| S:1080 E:1089 ||| VBN
therapies  ||| S:1089 E:1099 ||| NNS
specifically  ||| S:1099 E:1112 ||| RB
directed  ||| S:1112 E:1121 ||| VBN
against  ||| S:1121 E:1129 ||| IN
B-lymphocytes  ||| S:1129 E:1143 ||| NNP
( ||| S:1143 E:1144 ||| -LRB-
such  ||| S:1144 E:1149 ||| JJ
as  ||| S:1149 E:1152 ||| IN
rituximab ||| S:1152 E:1161 ||| CD
) ||| S:1161 E:1162 ||| -RRB-
.  ||| S:1162 E:1164 ||| .
Preliminary  ||| S:1164 E:1176 ||| JJ
results  ||| S:1176 E:1184 ||| NNS
on  ||| S:1184 E:1187 ||| IN
the  ||| S:1187 E:1191 ||| DT
use  ||| S:1191 E:1195 ||| NN
of  ||| S:1195 E:1198 ||| IN
these  ||| S:1198 E:1204 ||| DT
medications  ||| S:1204 E:1216 ||| NNS
are  ||| S:1216 E:1220 ||| VBP
promising ||| S:1220 E:1229 ||| VBG
.  ||| S:1229 E:1231 ||| .
Furthermore ||| S:1231 E:1242 ||| RB
,  ||| S:1242 E:1244 ||| ,
the  ||| S:1244 E:1248 ||| DT
use  ||| S:1248 E:1252 ||| NN
of  ||| S:1252 E:1255 ||| IN
biological  ||| S:1255 E:1266 ||| JJ
agents  ||| S:1266 E:1273 ||| NNS
in  ||| S:1273 E:1276 ||| IN
small  ||| S:1276 E:1282 ||| JJ
open  ||| S:1282 E:1287 ||| JJ
trials  ||| S:1287 E:1294 ||| NNS
in  ||| S:1294 E:1297 ||| IN
HCV  ||| S:1297 E:1301 ||| NNP
positive  ||| S:1301 E:1310 ||| JJ
arthritis  ||| S:1310 E:1320 ||| NN
patients  ||| S:1320 E:1329 ||| NNS
has  ||| S:1329 E:1333 ||| VBZ
demonstrated  ||| S:1333 E:1346 ||| VBN
an  ||| S:1346 E:1349 ||| DT
acceptable  ||| S:1349 E:1360 ||| JJ
safety  ||| S:1360 E:1367 ||| NN
profile ||| S:1367 E:1374 ||| NN
.  ||| S:1374 E:1376 ||| .
All  ||| S:1376 E:1380 ||| PDT
these  ||| S:1380 E:1386 ||| DT
empirical  ||| S:1386 E:1396 ||| JJ
observations  ||| S:1396 E:1409 ||| NNS
should  ||| S:1409 E:1416 ||| MD
probably  ||| S:1416 E:1425 ||| RB
induce  ||| S:1425 E:1432 ||| VB
the  ||| S:1432 E:1436 ||| DT
scientific  ||| S:1436 E:1447 ||| JJ
community  ||| S:1447 E:1457 ||| NN
to  ||| S:1457 E:1460 ||| TO
reconsider  ||| S:1460 E:1471 ||| VB
the  ||| S:1471 E:1475 ||| DT
therapeutical  ||| S:1475 E:1489 ||| JJ
approach  ||| S:1489 E:1498 ||| NN
to  ||| S:1498 E:1501 ||| TO
HCV-related  ||| S:1501 E:1513 ||| JJ
mixed  ||| S:1513 E:1519 ||| JJ
cryoglobulinemia ||| S:1519 E:1535 ||| NN
.  ||| S:1535 E:1537 ||| .
Indeed ||| S:1537 E:1543 ||| RB
,  ||| S:1543 E:1545 ||| ,
the  ||| S:1545 E:1549 ||| DT
use  ||| S:1549 E:1553 ||| NN
of  ||| S:1553 E:1556 ||| IN
aggressive  ||| S:1556 E:1567 ||| JJ
chemotherapy  ||| S:1567 E:1580 ||| JJ
treatments  ||| S:1580 E:1591 ||| NNS
in  ||| S:1591 E:1594 ||| IN
the  ||| S:1594 E:1598 ||| DT
era  ||| S:1598 E:1602 ||| NN
preceding  ||| S:1602 E:1612 ||| VBG
HCV  ||| S:1612 E:1616 ||| NNP
discovery  ||| S:1616 E:1626 ||| NN
has  ||| S:1626 E:1630 ||| VBZ
not  ||| S:1630 E:1634 ||| RB
been  ||| S:1634 E:1639 ||| VBN
associated  ||| S:1639 E:1650 ||| VBN
with  ||| S:1650 E:1655 ||| IN
significant  ||| S:1655 E:1667 ||| JJ
liver  ||| S:1667 E:1673 ||| NN
toxicities  ||| S:1673 E:1684 ||| NNS
and  ||| S:1684 E:1688 ||| CC
standard  ||| S:1688 E:1697 ||| JJ
chemotherapy  ||| S:1697 E:1710 ||| NN
during  ||| S:1710 E:1717 ||| IN
HCV-related  ||| S:1717 E:1729 ||| JJ
lymphoma  ||| S:1729 E:1738 ||| NN
carried  ||| S:1738 E:1746 ||| VBD
out  ||| S:1746 E:1750 ||| RP
a  ||| S:1750 E:1752 ||| DT
unexpected  ||| S:1752 E:1763 ||| JJ
low  ||| S:1763 E:1767 ||| JJ
rate  ||| S:1767 E:1772 ||| NN
of  ||| S:1772 E:1775 ||| IN
severe  ||| S:1775 E:1782 ||| JJ
liver  ||| S:1782 E:1788 ||| NN
damage ||| S:1788 E:1794 ||| NN
.  ||| S:1794 E:1796 ||| .
Future  ||| S:1796 E:1803 ||| JJ
efforts  ||| S:1803 E:1811 ||| NNS
should  ||| S:1811 E:1818 ||| MD
probably  ||| S:1818 E:1827 ||| RB
focus  ||| S:1827 E:1833 ||| VB
on  ||| S:1833 E:1836 ||| IN
the  ||| S:1836 E:1840 ||| DT
potential  ||| S:1840 E:1850 ||| JJ
benefit  ||| S:1850 E:1858 ||| NN
of  ||| S:1858 E:1861 ||| IN
a  ||| S:1861 E:1863 ||| DT
multi-step ||| S:1863 E:1873 ||| JJ
,  ||| S:1873 E:1875 ||| ,
combined  ||| S:1875 E:1884 ||| VBN
anti-viral  ||| S:1884 E:1895 ||| JJ
and  ||| S:1895 E:1899 ||| CC
cytotoxic  ||| S:1899 E:1909 ||| JJ
therapy  ||| S:1909 E:1917 ||| NN
( ||| S:1917 E:1918 ||| -LRB-
both  ||| S:1918 E:1923 ||| DT
with  ||| S:1923 E:1928 ||| IN
standard  ||| S:1928 E:1937 ||| JJ
regimens  ||| S:1937 E:1946 ||| NN
and  ||| S:1946 E:1950 ||| CC
new  ||| S:1950 E:1954 ||| JJ
medications ||| S:1954 E:1965 ||| NN
) ||| S:1965 E:1966 ||| -RRB-
.  ||| S:1966 E:1968 ||| .
